Concepedia

Alice Tsai

AT

11

Publications

846

Citations

11

H-Index

2014

Active since

Affiliations

Vertex Pharmaceuticals (United States)(Current)

Takeda (United States)

Pfizer (United States)

AbbVie (United States)

GlaxoSmithKline (United States)

Alice Tsai is an author at Vertex Pharmaceuticals (United States) specializing in drug discovery, medicine, and pharmacology.

ORCID

Top concepts

Publications per year

2014–2025

11

Publications

11

Discovery of a Novel, First-in-Class, Orally Bioavailable Azaindole Inhibitor (VX-787) of Influenza PB2

Michael P. Clark, Mark W. Ledeboer, Ioana Davies et al. · Journal of Medicinal Chemistry · 2014 · 207 citations · Full text

, , +13

Preclinical Activity of VX-787, a First-in-Class, Orally Bioavailable Inhibitor of the Influenza Virus Polymerase PB2 Subunit

Randal A. Byrn, Steven J.M. Jones, Hamilton B. Bennett et al. · Antimicrobial Agents and Chemotherapy · 2014 · 185 citations · Full text

Physiologically‐Based Pharmacokinetic Modeling in Renal and Hepatic Impairment Populations: A Pharmaceutical Industry Perspective

Tycho Heimbach, Yuan Chen, Jun Chen et al. · Clinical Pharmacology & Therapeutics · 2020 · 119 citations · Full text

Applications of Quantitative Systems Pharmacology in Model‐Informed Drug Discovery: Perspective on Impact and Opportunities

Erica L. Bradshaw, Mary E. Spilker, Richard Zang et al. · CPT Pharmacometrics & Systems Pharmacology · 2019 · 85 citations · Full text

Discovery of TNG908: A Selective, Brain Penetrant, MTA-Cooperative PRMT5 Inhibitor That Is Synthetically Lethal with <i>MTAP</i>-Deleted Cancers

Kevin M. Cottrell, Kimberly J. Briggs, Douglas A. Whittington et al. · Journal of Medicinal Chemistry · 2024 · 58 citations · Full text

Rows per page

1–5 of 11